imgn632

mAbexperimentalADC

Clinical trial activity

5 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jan 4, 2018 (NCT03386513)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No
Payload
indolinobenzodiazepine pseudodimer

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07306832Phase 1Jan 14, 2026AbbVie
NCT06034470Phase 1Jan 13, 2024Immunogen, University of Washington
NCT05320380Phase 1/Phase 2 (Phase 2)Dec 20, 2022Immunogen, LLS PedAL Initiative, LLC, National Cancer Institute (NCI)
NCT04086264Phase 1/Phase 2 (Phase 2)Oct 16, 2019Immunogen
NCT03386513Phase 1Jan 4, 2018Immunogen, Jazz Pharmaceuticals
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ImmunogenFor profit4122018
AbbVieFor profit1112026
Jazz PharmaceuticalsFor profit1012018
LLS PedAL Initiative, LLCAcademic/Hospital1112022
National Cancer Institute (NCI)Government1012022
University of WashingtonAcademic/Hospital1112024
6 organizations
Page 1 / 1